Compounds > miglustat
Page last updated: 2024-08-23

miglustat and Diarrhea

miglustat has been researched along with Diarrhea in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gianutsos, J; Kolodny, EH; Luzy, C; Pastores, GM; Shapiro, BE1
Banwell, B; Clarke, JT; Dingemanse, J; Maegawa, GH; Morgan, CP; Tifft, CJ; van Giersbergen, PL; Yang, S1
Abel, L; Chadha-Boreham, H; Giorgino, R; Jacklin, E; Luzy, C; Patterson, MC; Vecchio, D; Wraith, JE1
Aspinall, RL; Collier, AC; Coombs, R; Fass, RJ; Fife, KH; Fischl, MA; Kremer, AB; Pottage, JC; Powderly, WG; Resnick, L1
Fischl, M; Karim, A; Kessler, H; Merigan, T; Pottage, J; Powderly, W; Richman, D; Sherman, J; Smith, S; Tierney, M1
Aerts, J; Butters, T; Cox, T; Dwek, R; Elstein, D; Gow, I; Hollak, C; Hrebícek, M; Lachmann, R; Moyses, C; Platt, F; van Weely, S; Zimran, A1

Trials

6 trial(s) available for miglustat and Diarrhea

ArticleYear
Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2009, Volume: 11, Issue:6

    Topics: 1-Deoxynojirimycin; Adolescent; Adult; Age of Onset; Diarrhea; Enzyme Inhibitors; Fatigue; Female; Glycoside Hydrolase Inhibitors; Humans; Male; Middle Aged; Tay-Sachs Disease; Time Factors; Treatment Outcome; Weight Loss; Young Adult

2009
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
    Molecular genetics and metabolism, 2009, Volume: 97, Issue:4

    Topics: 1-Deoxynojirimycin; Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Gangliosidoses, GM2; Glucosyltransferases; Humans; Infant

2009
Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial.
    Molecular genetics and metabolism, 2010, Volume: 99, Issue:4

    Topics: 1-Deoxynojirimycin; Adolescent; Adult; Child; Deglutition; Diarrhea; Female; Humans; Niemann-Pick Disease, Type C; Walking; Weight Loss

2010
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
    Journal of acquired immune deficiency syndromes, 1994, Volume: 7, Issue:2

    Topics: 1-Deoxynojirimycin; Adult; Antiviral Agents; beta 2-Microglobulin; CD4-Positive T-Lymphocytes; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Neutrophils; Paresthesia; RNA, Viral; Zidovudine

1994
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Dec-15, Volume: 10, Issue:5

    Topics: 1-Deoxynojirimycin; Adult; Animals; Antiviral Agents; Cataract; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Diarrhea; Female; Flatulence; Half-Life; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lens, Crystalline; Leukopenia; Liver; Male; Neutropenia; Rats

1995
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Lancet (London, England), 2000, Apr-29, Volume: 355, Issue:9214

    Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; Aged; Diarrhea; Enzyme Inhibitors; Female; Gaucher Disease; Glucosyltransferases; Half-Life; Hexosaminidases; Humans; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Spleen; Tomography, X-Ray Computed

2000